Evaluation of Adverse Events of Oral Antihyperglycaemic Monotherapy Experienced by a Geriatric Population in a Real-World Setting

[1]  E. Salpeter,et al.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2010, The Cochrane database of systematic reviews.

[2]  B. Zinman,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.

[3]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. , 2007, The New England journal of medicine.

[4]  G. Nichols,et al.  Weight changes following the initiation of new anti‐hyperglycaemic therapies , 2007, Diabetes, obesity & metabolism.

[5]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[6]  D. Sclar,et al.  Trends in the Prescribing of Oral Agents for the Management of Type 2 Diabetes Mellitus in the United States, 1990-2001 , 2006, The Diabetes educator.

[7]  B. Zinman,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2006, Diabetes Care.

[8]  Michael M. Engelgau,et al.  Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population , 2006, Diabetes Care.

[9]  C. Ryan,et al.  Improving metabolic control leads to better working memory in adults with type 2 diabetes. , 2006, Diabetes care.

[10]  R. Urquhart,et al.  Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. , 2005, Diabetes research and clinical practice.

[11]  M. Hanefeld,et al.  A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[12]  K. Fujioka,et al.  Efficacy, dose–response relationship and safety of once‐daily extended‐release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double‐blind, placebo‐controlled studies , 2005, Diabetes, obesity & metabolism.

[13]  M. Hanefeld,et al.  Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. , 2004, The Journal of clinical endocrinology and metabolism.

[14]  A. Novials,et al.  GUIDE study: double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patients , 2004, European journal of clinical investigation.

[15]  S. Mudaliar,et al.  Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[16]  A. Garber,et al.  Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[17]  A. Luger,et al.  Effects of glimepiride on HbA1c and body weight in Type 2 diabetes: results of a 1.5-year follow-up study , 2003 .

[18]  Arleen F. Brown,et al.  Income‐Related Differences in the Use of Evidence‐Based Therapies in Older Persons with Diabetes Mellitus in For‐Profit Managed Care , 2003, Journal of the American Geriatrics Society.

[19]  C. Mangione,et al.  Guidelines for improving the care of the older person with diabetes mellitus. , 2003, Journal of the American Geriatrics Society.

[20]  H. Lochnan,et al.  A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. , 2003, Clinical therapeutics.

[21]  T. Ogihara,et al.  Less frequent body weight gain in elderly type 2 diabetic patients treated with glimepiride , 2003 .

[22]  P. Hogan,et al.  Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.

[23]  M. Massi-Benedetti.  Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. , 2003, Clinical therapeutics.

[24]  I. Deary,et al.  Type 2 diabetes and cognitive impairment , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[25]  M. Engelgau,et al.  Complications of diabetes in elderly people , 2002, BMJ : British Medical Journal.

[26]  A. Garber,et al.  Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes , 2002, Diabetes, obesity & metabolism.

[27]  H. Lebovitz,et al.  Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. , 2002, Diabetes care.

[28]  S. Inzucchi.  Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.

[29]  G. Grunberger,et al.  Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. , 2001, Diabetes care.

[30]  J. Mckinlay,et al.  US public health and the 21st century: diabetes mellitus , 2000, The Lancet.

[31]  P. Savage,et al.  Antidiabetic treatment trends in a cohort of elderly people with diabetes. The cardiovascular health study, 1989-1997. , 1999, Diabetes care.

[32]  H. Ben-Ami,et al.  Drug-induced hypoglycemic coma in 102 diabetic patients. , 1999, Archives of internal medicine.

[33]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[34]  L. Jovanovič,et al.  A Placebo‐Controlled, Randomized Study of Glimepiride in Patients with Type 2 Diabetes Mellitus for Whom Diet Therapy is Unsuccessful , 1998, Journal of clinical pharmacology.

[35]  A. Garber,et al.  Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. , 1997, The American journal of medicine.

[36]  A. Hofman,et al.  Insulin and Cognitive Function in an Elderly Population: The Rotterdam Study , 1997, Diabetes Care.

[37]  H. Inadera,et al.  Diabetic Control and Progression of Retinopathy in Elderly Patients: Five‐Year Follow‐up Study , 1994, Journal of the American Geriatrics Society.

[38]  D. Nathan,et al.  Long-term complications of diabetes mellitus. , 1993, The New England journal of medicine.

[39]  H S Seltzer,et al.  Drug-induced hypoglycemia. A review of 1418 cases. , 1989, Endocrinology and metabolism clinics of North America.

[40]  S. Bowlin,et al.  Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. , 2004, Diabetes care.

[41]  Glycaemic control in diabetes. , 2003, Clinical evidence.

[42]  G. Meneilly,et al.  Diabetes in elderly adults. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[43]  H. Lebovitz,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes , 1999 .